Azathioprine

Azathioprine

SCHEMBL26152

Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12.Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12.[Na+]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPAT

The experimentally established mechanism targets of Azathioprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.98
HBB P68871 2/20 0.98
LMNA P02545 2/20 0.98
TP53 P04637 2/20 0.98
GMNN O75496 1/20 0.98
PGR P06401 1/20 0.98
CYP3A4 P08684 1/20 0.98
SLC6A4 P31645 1/20 0.98
BLM P54132 1/20 0.98
PMP22 Q01453 1/20 0.98
SMN1; SMN2 Q16637 1/20 0.98
TDP1 Q9NUW8 1/20 0.98
KDM4E B2RXH2 1/20 0.69
NPC1 O15118 1/20 0.69
ALDH1A1 P00352 4/20 0.52
RAB9A P51151 1/20 0.52
HTT P42858 2/20 0.49
HPGD P15428 2/20 0.49
GFER P55789 3/20 0.48
CYP2C19 P33261 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azathioprine SCHEMBL317904 1.00 MAPT (0.98) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL4278 0.99 MAPT (1.00) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL4436347 0.99 MAPT (1.00) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL29693611 0.99 MAPT (1.00) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL3089846 0.98 MAPT (0.98) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL502599 0.98 MAPT (0.98) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL4259183 0.91 MAPT (0.84) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL8354969 0.90 MAPT (0.82) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL8511946 0.90 MAPT (0.82) MAPTHBBLMNATP53GMNN
Azathioprine SCHEMBL2328735 0.90 MAPT (0.82) MAPTHBBLMNATP53GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10058641-B2 Medical devices containing rapamycin analogs ABBOTT LABORATORIES (US) 2018-08-28 US disclosed
EP-3175870-A1 MEDICAL DEVICE HAVING HYDRATION INHIBITOR Abbott Laboratories (US) 2017-06-07 EP disclosed
EP-3138531-A1 COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS USING MEDICAL DEVICES FOR LONG-TERM EFFICACY Abbott Laboratories (US) 2017-03-08 EP disclosed
EP-2358299-B1 BODY LUMEN FILTER RETRIEVAL SYSTEM AND METHODS FOR FILTERING A BODY LUMEN ABBOTT LABORATORIES VASCULAR ENTPR LTD (IE) 2017-02-15 EP disclosed
US-9504551-B2 Apparatus for filtering a body lumen ABBOTT LABORATORIES VASCULAR ENTERPRISES LIMITED (IE) 2016-11-29 US disclosed
EP-2387373-B1 METHODS AND APPARATUS FOR FILTERING A BODY LUMEN ABBOTT LAB VASCULAR ENTPR LTD (IE) 2016-10-12 EP disclosed
EP-1427457-B1 MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS ABBOTT LAB (US) 2016-08-17 EP disclosed
US-20160220739-A1 MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS ABBOTT LAB (US) 2016-08-04 US disclosed
US-9375304-B2 Methods and apparatus for filtering a body lumen ABBOTT LABORATORIES VASCULAR ENTERPRISES LIMITED (IE) 2016-06-28 US disclosed
EP-2493419-B1 Medical device for treatment of a lumen ABBOTT LAB VASCULAR ENTPR LTD (IE) 2016-05-04 EP disclosed
EP-0877554-A4 1998-12-02 EP disclosed
EP-0877554-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY Merck & Co., Inc. (US) 1998-11-18 EP disclosed
EP-0858332-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY Merck & Co., Inc. (US) 1998-08-19 EP disclosed
EP-0858456-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY Merck & Co., Inc. (US) 1998-08-19 EP disclosed
WO-1998016532-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY MERCK & CO., INC. (US) 1998-04-23 WO disclosed
WO-1998016518-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY MERCK & CO., INC. (US) 1998-04-23 WO disclosed
WO-1998016531-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPRESSANT ACTIVITY MERCK & CO., INC. (US) 1998-04-23 WO disclosed
WO-1997016068-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY MERCK & CO., INC. (US) 1997-05-09 WO disclosed
WO-1997016182-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY MERCK & CO., INC. (US) 1997-05-09 WO disclosed
WO-1997016437-A1 TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY MERCK & CO., INC. (US) 1997-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10058641-B2 Medical devices containing rapamycin analogs PGF, RICTOR, MMP9 MAPT 3642/4885HBB 2897/4885LMNA 3079/4885
US-20160220739-A1 MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS PGF, RICTOR, MMP9 MAPT 3642/4885HBB 2897/4885LMNA 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.